Clinical experience for testifying the efficacy and safety of Nateglinide in treating type 2 diabetes

Objective To testify the efficacy and safety of a new oral hypoglycemic agent——Nateglinide in treating type 2 diabetic patients. Methods Forty-six patients with type 2 diabetes mellitus were divided into Nateglinide medication group and control group(Repaglinide group)and the subjects were administered with medicines for 12 weeks. Fasting finger point blood glucose,2 h postprandial blood glucose, fasting plasma glucose,2 h postprandial blood plasma glucose and HbA1c were measured. Results ①The results showed that Nateglinide reduced the mean fasting and 2 h postprandial blood glucose and HbA1c levels by 1.63 mmol/L, 4.43 mmol/L, 1.71% respectively.②There were no significantly difference in fasting and 2 h postprandial blood glucose between two groups after treatment.③Blood cholesterol ,body weight and blood pressure did not significantly change after treatment.④There were no hypoglycemia and gastrointestinal symptoms during medical treatment. Conclusion This result provides an efficacy in metabolic control and a safety profile of nateglinide in the treatment of type 2 diabetes.